| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $40,024,533 | 42 | 100 |
| TANNENBAUM RENEE P | director | 0 | $0 | 1 | $146,070 | $-146,070 |
| Mutz Christopher | HEAD OF RARE DISEASE | 0 | $0 | 1 | $241,800 | $-241,800 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 0 | $0 | 12 | $373,065 | $-373,065 |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | 0 | $0 | 1 | $426,407 | $-426,407 |
| Davis Krista | SVP, CHIEF HR OFFICER | 0 | $0 | 6 | $634,652 | $-634,652 |
| Leonard Matthew J | director | 0 | $0 | 2 | $840,723 | $-840,723 |
| Gutwerg Ori | SVP, GENERICS | 0 | $0 | 3 | $884,161 | $-884,161 |
| Pera Antonio R | director | 0 | $0 | 2 | $1.18M | $-1.18M |
| Walsh Patrick D | director | 0 | $0 | 2 | $1.55M | $-1.55M |
| HAUGHEY THOMAS | director | 0 | $0 | 1 | $1.66M | $-1.66M |
| Thoma Jeanne | director | 0 | $0 | 1 | $1.92M | $-1.92M |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 0 | $0 | 3 | $3.05M | $-3.05M |
| CAREY STEPHEN P. | SVP & CFO | 0 | $0 | 1 | $4.3M | $-4.3M |
| Lalwani Nikhil | PRESIDENT & CEO | 0 | $0 | 1 | $4.89M | $-4.89M |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 0 | $0 | 5 | $17.91M | $-17.91M |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Over the last 12 months, insiders at ANI Pharmaceuticals, Inc. have bought $0 and sold $40.02M worth of ANI Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ANI Pharmaceuticals, Inc. have bought $511,502 and sold $32.65M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $138,794 was made by Walsh Patrick D () on 2022‑03‑21.
| 2026-01-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 500 0.0023% | $84.33 | $42,165 | +5.19% | |
| 2025-12-18 | Sale | Davis Krista | SVP, CHIEF HR OFFICER | 1,622 0.0072% | $82.40 | $133,653 | -2.55% | |
| 2025-12-12 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0018% | $82.32 | $32,928 | +0.88% | |
| 2025-12-05 | Sale | TANNENBAUM RENEE P | director | 1,800 0.008% | $81.15 | $146,070 | -0.50% | |
| 2025-11-13 | Sale | Gassert Chad | SVP - CORP. DEV. & STRATEGY | 94 0.0004% | $88.00 | $8,272 | -3.41% | |
| 2025-11-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0018% | $87.27 | $34,908 | -3.41% | |
| 2025-11-13 | Sale | Walsh Patrick D | director | 8,643 0.0395% | $86.88 | $750,904 | -3.41% | |
| 2025-11-12 | Sale | Gassert Chad | SVP - CORP. DEV. & STRATEGY | 14,642 0.0665% | $89.07 | $1.3M | -6.36% | |
| 2025-10-13 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0019% | $90.09 | $36,036 | -6.51% | |
| 2025-09-19 | Sale | Davis Krista | SVP, CHIEF HR OFFICER | 1,000 0.0047% | $98.04 | $98,040 | -12.49% | |
| 2025-09-12 | Sale | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0019% | $98.42 | $39,368 | -11.47% | |
| 2025-09-03 | Sale | Pera Antonio R | director | 7,292 0.0336% | $94.94 | $692,302 | -6.58% | |
| 2025-08-25 | Sale | Leonard Matthew J | director | 2,528 0.0116% | $90.62 | $229,087 | -1.04% | |
| 2025-08-22 | Sale | Davis Krista | SVP, CHIEF HR OFFICER | 1,763 0.0081% | $91.10 | $160,609 | -1.51% | |
| 2025-08-21 | Sale | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 52,988 0.2424% | $90.44 | $4.79M | -1.56% | |
| 2025-08-20 | Sale | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 47,012 0.2159% | $90.27 | $4.24M | -0.92% | |
| 2025-08-20 | Sale | Pera Antonio R | director | 5,421 0.0247% | $89.73 | $486,426 | -0.92% | |
| 2025-08-18 | Sale | Thoma Jeanne | director | 21,540 0.0987% | $89.15 | $1.92M | +0.43% | |
| 2025-08-18 | Sale | Leonard Matthew J | director | 6,937 0.0314% | $88.17 | $611,635 | +0.43% | |
| 2025-08-15 | Sale | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 52,990 0.2435% | $87.15 | $4.62M | +2.83% |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 431920 1.9232% | $36.64M | 1 | 61 | +24.75% |
| Lalwani Nikhil | PRESIDENT & CEO | 411219 1.831% | $34.88M | 1 | 7 | +31.46% |
| CAREY STEPHEN P. | SVP & CFO | 180863 0.8053% | $15.34M | 0 | 5 | |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 158490 0.7057% | $13.44M | 1 | 13 | +29.72% |
| Mutz Christopher | HEAD OF RARE DISEASE | 107317 0.4779% | $9.1M | 0 | 5 | |
| Gutwerg Ori | SVP, GENERICS | 84024 0.3741% | $7.13M | 0 | 5 | |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 74374 0.3312% | $6.31M | 0 | 26 | |
| Walsh Patrick D | director | 61405 0.2734% | $5.21M | 4 | 2 | +15.33% |
| Davis Krista | SVP, CHIEF HR OFFICER | 58564 0.2608% | $4.97M | 0 | 8 | |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | 40794 0.1816% | $3.46M | 0 | 1 | |
| HAUGHEY THOMAS | director | 36521 0.1626% | $3.1M | 4 | 1 | <0.0001% |
| TANNENBAUM RENEE P | director | 25157 0.112% | $2.13M | 0 | 2 | |
| Thoma Jeanne | director | 23405 0.1042% | $1.99M | 1 | 1 | <0.0001% |
| Pera Antonio R | director | 22660 0.1009% | $1.92M | 1 | 4 | <0.0001% |
| Leonard Matthew J | director | 6864 0.0306% | $582,273.12 | 0 | 2 | |
| MERIDIAN VENTURE PARTNERS II LP | 10 percent owner | 1819259 8.1007% | $154.33M | 0 | 18 | |
| MORGENSTERN VICTOR A | director | 455571 2.0285% | $38.65M | 2 | 0 | +243.13% |
| MARSHBANKS TRACY | director | 349934 1.5582% | $29.68M | 0 | 16 | |
| RAYNOR DANIEL | director | 289003 1.2869% | $24.52M | 0 | 8 | |
| EDELMAN JOSEPH | 10 percent owner | 209100 0.9311% | $17.74M | 23 | 7 | <0.0001% |
| PRZYBYL ARTHUR | President and CEO | 202589 0.9021% | $17.19M | 2 | 10 | +64.77% |
| SIMES STEPHEN M | Vice Chairman, President & CEO | 202167 0.9002% | $17.15M | 4 | 1 | +6.23% |
| Marken James G. | SVP OPS & PROD DEV | 124492 0.5543% | $10.56M | 0 | 9 | |
| HOLUBOW FRED | director | 61259 0.2728% | $5.2M | 1 | 2 | |
| Schrepfer Robert W | SVP - New Bus Dev & Spec Sales | 55927 0.249% | $4.74M | 0 | 5 | |
| SULLIVAN LOUIS W | director | 47898 0.2133% | $4.06M | 2 | 0 | |
| DONENBERG PHILIP B | Sr. VP of Finance, CFO & Secy | 44322 0.1974% | $3.76M | 8 | 0 | +32.33% |
| KJAER PETER | director | 34425 0.1533% | $2.92M | 2 | 0 | +3.25% |
| MANGANO ROSS J | director | 26914 0.1198% | $2.28M | 19 | 0 | +73.75% |
| Arnold Charlotte C. | Vice President and CFO | 21385 0.0952% | $1.81M | 0 | 1 | |
| ROSENOW EDWARD C III | director | 20540 0.0915% | $1.74M | 1 | 0 | |
| NASH DAVID | director | 5236 0.0233% | $444,169.88 | 1 | 0 | <0.0001% |
| BELL STEVEN J | VP Research & Pre-Clinical Dev | 875 0.0039% | $74,226.25 | 0 | 9 | |
| LEHMAN LEAH M | VP, Product Development | 0 0% | $0 | 1 | 5 |
$910,099,463 | 123 | 11.52% | $2.59B | |
$13,087,863 | 76 | 19.19% | $2.1B | |
$25,130,034 | 62 | -7.01% | $12.19B | |
ANI Pharmaceuticals, Inc. (ANIP) | $14,599,168 | 59 | 12.79% | $1.91B |
$102,709,455 | 46 | 30.55% | $824.29M | |
$11,542,910 | 40 | 56.19% | $1.77B | |
$73,312,053 | 38 | -4.37% | $2.07B | |
$21,020,549 | 38 | -2.84% | $13.2B | |
$21,068,600 | 35 | 9.64% | $1.84B | |
$12,998,723 | 30 | 3.46% | $4.22B | |
$6,506,230 | 27 | -16.20% | $968.76M | |
$83,406,412 | 19 | 21.96% | $2.87B | |
$2,233,486 | 16 | -3.34% | $14.81B | |
$1,843,996 | 10 | 22.92% | $1.2B | |
$1,718,514 | 9 | 38.12% | $957.3M | |
$26,633,903 | 9 | 42.23% | $1.44B | |
$141,200 | 8 | 41.74% | $4.37B | |
$614,633 | 6 | 27.88% | $1.66B | |
$543,932 | 6 | -22.06% | $733.64M |
| Increased Positions | 142 | +52.4% | 5M | +23.32% |
| Decreased Positions | 115 | -42.44% | 4M | -19.6% |
| New Positions | 62 | New | 2M | New |
| Sold Out Positions | 28 | Sold Out | 330,138 | Sold Out |
| Total Postitions | 298 | +9.96% | 21M | +3.72% |
| Blackrock, Inc. | $199,910.00 | 11.59% | 2.55M | -31,645 | -1.23% | 2025-09-30 |
| Vanguard Group Inc | $100,192.00 | 5.81% | 1.28M | +116 | +<0.01% | 2025-09-30 |
| State Street Corp | $55,819.00 | 3.24% | 711,708 | -4,409 | -0.62% | 2025-09-30 |
| Global Alpha Capital Management Ltd. | $49,457.00 | 2.87% | 630,590 | -231,500 | -26.85% | 2025-09-30 |
| Ubs Group Ag | $46,264.00 | 2.68% | 589,874 | +185,172 | +45.76% | 2025-09-30 |
| Citadel Advisors Llc | $45,496.00 | 2.64% | 580,085 | +10,455 | +1.83% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $39,641.00 | 2.3% | 505,428 | -48,465 | -8.75% | 2025-09-30 |
| Geode Capital Management, Llc | $35,922.00 | 2.08% | 458,014 | +30,468 | +7.13% | 2025-09-30 |
| Deep Track Capital, Lp | $35,294.00 | 2.05% | 450,000 | -250,000 | -35.71% | 2025-09-30 |
| Point72 Asset Management, L.P. | $31,301.00 | 1.81% | 399,092 | +399,092 | New | 2025-09-30 |